medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-253Research ArticleСтатьиПолипрагмазия или ЭСТ? Сравнительная характеристика побочных эффектов у больных с резистентной шизофрениейPolypharmacy or ECT? Side effects profile comparison in patients with resistant schizophreniaЗубовД. С.ZubovD. S.noemail@neicon.ruФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Минздрава РоссииRussian Federation201709072017221Больница — все для ЛПУ5257Copyright © Зубов Д.С., 20172017Зубов Д.С.Zubov D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/253

Работа посвящена анализу выраженности и частоты встречаемости побочных эффектов у пациентов, страдающих терапевтически резистентной шизофренией. При помощи шкалы UKU проведено сравнение спектра и степени выраженности побочных эффектов между двумя группами пациентов: получающих комплексную электросудорожную терапию (ЭСТ) и антипсихотики и только медикаментозное лечение. Выявлено, что у пациентов, получающих комплексную терапию ЭСТ и антипсихотиками, определенные группы побочных эффектов имеют меньшую степень выраженности и большую степень редукции в процессе терапии по сравнению с пациентами, получающими только медикаментозное лечение.

The data about treatment resistant paranoid schizophrenia patients getting electroconvulsive therapy (ECT) together with antipsychotic agents and about the patients receiving combined antipsychotics treatment only is observed in the article. The side effects spectrum is analyzed with the help of UKU standardized scale. Patients getting combined ECT and antipsychotics treatment have less intensity and greater reduction of some specific side effects groups during the course of antipsychotic treatment.

электросудорожная терапияантипсихотические средствапобочные эффектыпереносимостьбезопасностьelectroconvulsive therapyantipsychotic agentsside effectstolerabilitysafetyReferencesMcGrath J., Saha S., Chant D. et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. // Epidemiologic Reviews. - 2008. - Vol. 30. - P. 67-76.McGrath J., Saha S., Chant D. et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. // Epidemiologic Reviews. - 2008. - Vol. 30. - P. 67-76.Bayley R. First person account: schizophrenia. // Schizophrenia Bulletin. - 1996. - Vol. 22 (4). - P. 727-729.Bayley R. First person account: schizophrenia. // Schizophrenia Bulletin. - 1996. - Vol. 22 (4). - P. 727-729.Altamura C., Fagiolini A., Galderisi S. et al. Schizophrenia today: epidemiology, diagnosis, course and models of care // Journal of Psychopathology. - 2014. - Vol. 20. - P. 223-243.Altamura C., Fagiolini A., Galderisi S. et al. Schizophrenia today: epidemiology, diagnosis, course and models of care // Journal of Psychopathology. - 2014. - Vol. 20. - P. 223-243.Caccia S., Invernizzi R. W., Nobili A. et al. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. // Ther Clin Risk Manag. - 2013. - Vol. 9. - P. 319-328.Caccia S., Invernizzi R. W., Nobili A. et al. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. // Ther Clin Risk Manag. - 2013. - Vol. 9. - P. 319-328.Abbott C. C., Jaramillo A., Wilcox C. E. et al. Antipsychotic Drug Effects in Schizophrenia: A Review of Longitudinal fMRI Investigations and Neural Interpretations. // Curr Med Chem. - 2013. - Vol. 20 (3). - P. 428-437.Abbott C. C., Jaramillo A., Wilcox C. E. et al. Antipsychotic Drug Effects in Schizophrenia: A Review of Longitudinal fMRI Investigations and Neural Interpretations. // Curr Med Chem. - 2013. - Vol. 20 (3). - P. 428-437.Gallini A., Huskamp H.A., Donohue J.M. Technology diffusion in the antipsychotic market: a comparison of France and the USA between 1998 and 2008. // Psychiatric Services. - 2013. - Vol. 64 (7). - P. 680-687.Gallini A., Huskamp H.A., Donohue J.M. Technology diffusion in the antipsychotic market: a comparison of France and the USA between 1998 and 2008. // Psychiatric Services. - 2013. - Vol. 64 (7). - P. 680-687.Hirsch L., Yang J., Bresee L. et al. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. // Drug Safety. - 2017.Hirsch L., Yang J., Bresee L. et al. Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. // Drug Safety. - 2017.Seong S. Shim. Treatment-Resistant Schizophrenia. // Psychiatric times. - 2009.Seong S. Shim. Treatment-Resistant Schizophrenia. // Psychiatric times. - 2009.Kane J., Honigfeld G., Singer J. et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorproma-zine. // Archives of General Psychiatry. - 1988. - Vol. 45 (9). - P. 789-796.Kane J., Honigfeld G., Singer J. et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorproma-zine. // Archives of General Psychiatry. - 1988. - Vol. 45 (9). - P. 789-796.Молосов С.Н. Резистентность к психофармакотерапии и методы её преодоления. // Психиатрия и психофармакотерапия. - 2002. - Том 4, № 4.Молосов С.Н. Резистентность к психофармакотерапии и методы её преодоления. // Психиатрия и психофармакотерапия. - 2002. - Том 4, № 4.Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. // Molecular Psychiatry. - 2008. - Vol. 13 (1). - P. 27-35.Nasrallah H.A. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. // Molecular Psychiatry. - 2008. - Vol. 13 (1). - P. 27-35.Englisch S., Zink M. Treatment-resistant Schizophrenia: Evidence-based Strategies. // Mens Sana Monographs. - 2012. - Vol. 10 (1). - P. 20-32.Englisch S., Zink M. Treatment-resistant Schizophrenia: Evidence-based Strategies. // Mens Sana Monographs. - 2012. - Vol. 10 (1). - P. 20-32.Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review. // CADTH Technol Overv. - 2012. - Vol. 2 (3).Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review. // CADTH Technol Overv. - 2012. - Vol. 2 (3).Mossaheb N., Kaufmann R.M. Role of aripiprazole in treatment-resistant schizophrenia. // Neuropsychiatr Dis Treat. - 2012. - Vol. 8. - P. 235-244.Mossaheb N., Kaufmann R.M. Role of aripiprazole in treatment-resistant schizophrenia. // Neuropsychiatr Dis Treat. - 2012. - Vol. 8. - P. 235-244.Ortiz-Orendain J., Castiello-de Obeso S., Colunga-Lozano L.E. et al. Antipsychotic combinations for schizophrenia. // The Cochrane Database of Systematic Reviews. - 2017.Ortiz-Orendain J., Castiello-de Obeso S., Colunga-Lozano L.E. et al. Antipsychotic combinations for schizophrenia. // The Cochrane Database of Systematic Reviews. - 2017.Greenhalgh J., Knight C., Hind D. et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. - 2005.Greenhalgh J., Knight C., Hind D. et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. - 2005.Dabrowski M., Parnowski M. Clinical analysis of safety and effectiveness of electroconvulsive therapy. // Psychiatria Polska. - 2012. - Vol. 46 (3). - P. 345-360.Dabrowski M., Parnowski M. Clinical analysis of safety and effectiveness of electroconvulsive therapy. // Psychiatria Polska. - 2012. - Vol. 46 (3). - P. 345-360.Watts B.V., Groft A., Bagian J.P. et al. An examination of mortality and other adverse events related to electroconvulsive therapy using a national adverse event report system. // The Journal of ECT. - 2011. - Vol. 27 (2). - P. 105-108.Watts B.V., Groft A., Bagian J.P. et al. An examination of mortality and other adverse events related to electroconvulsive therapy using a national adverse event report system. // The Journal of ECT. - 2011. - Vol. 27 (2). - P. 105-108.Andrade C., Arumugham S.S., Thirthalli J. Adverse Effects of Electroconvulsive Therapy. // The Psychiatric Clinics of North America. - 2016. - Vol. 39 (3). - P. 513-530.Andrade C., Arumugham S.S., Thirthalli J. Adverse Effects of Electroconvulsive Therapy. // The Psychiatric Clinics of North America. - 2016. - Vol. 39 (3). - P. 513-530.Payne N.A., Prudic J. Electroconvulsive Therapy Part I: A Perspective on the Evolution and Current Practice of ECT. // J Psychiatr Pract. - 2009. - Vol. 15 (5). - P. 346-368.Payne N.A., Prudic J. Electroconvulsive Therapy Part I: A Perspective on the Evolution and Current Practice of ECT. // J Psychiatr Pract. - 2009. - Vol. 15 (5). - P. 346-368.McFarquhar T.F., Thompson J. Knowledge and attitudes regarding electroconvulsive therapy among medical students and the general public. // The Journal of ECT. - 2008. - Vol. 24 (4). - P. 244-253.McFarquhar T.F., Thompson J. Knowledge and attitudes regarding electroconvulsive therapy among medical students and the general public. // The Journal of ECT. - 2008. - Vol. 24 (4). - P. 244-253.Голенков А. В. Отношение разных групп населения к электросудорожной терапии. // Медицинская психология в России. - 2011. - № 5 (10).Голенков А. В. Отношение разных групп населения к электросудорожной терапии. // Медицинская психология в России. - 2011. - № 5 (10).American Psychiatric Association Practice and Guidilenes for the Psychiatric Evaluation for Adults. - 2004.American Psychiatric Association Practice and Guidilenes for the Psychiatric Evaluation for Adults. - 2004.Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. // Schizophrenia Bulletin. - 1987. - 13 (2). - 261-76.Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. // Schizophrenia Bulletin. - 1987. - 13 (2). - 261-76.Lingjœrde O., Ahlfors U.G., Bech P., et al. UKU Side Effects Rating Scale // Acta Psychatr Scand. - 1987. - 76; Suppl. 334.Lingjœrde O., Ahlfors U.G., Bech P., et al. UKU Side Effects Rating Scale // Acta Psychatr Scand. - 1987. - 76; Suppl. 334.

The authors declare that there are no conflicts of interest present.